GLMD Galmed Pharmaceuticals
- 0.3614
- -0.0027-0.74%
Galmed Pharmaceuticals News
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CVI Investments, Inc.(9.9%),Heights Capital Management, Inc.(9.9%)
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Biotechnology Value Fund, L.P.(0%),BVF I GP LLC(0%), etc.
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Allen Baharaff(6.2%),G. Yarom Medical Research Ltd.(4.5%)
Galmed Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-CVI Investments, Inc.(9.9%),Heights Capital Management, Inc.(9.9%)
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BVF Partners L.P.(6.9%),BVF Inc.(6.9%), etc.
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Allen Baharaff(17.3%),G. Yarom Medical Research Ltd.(13.6%)
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nantahala Capital Management, LLC(1.2%),Wilmot B. Harkey(1.2%), etc.
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Allen Baharaff(16.9%),G. Yarom Medical Research Ltd.(13.6%)
Galmed Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ibex Investors LLC(1.4%),Justin B. Borus(1.4%), etc.
Galmed Pharmaceuticals | SC 13G: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Galmed Pharmaceuticals | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Analysis
Price Target
No Data
